Kudo M, Okusaka T, Motomura K, Ohno I, et al. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol 2020 Feb 27. pii: 10.1007/s00535-020-01668.
PMID: 32107609